All (n = 35) | Walk (n = 21) | Strength-Walk (n = 14) | |
---|---|---|---|
Demographic and general characteristics | |||
Male gendera | 26 (74%) | 12 (57%)a | 14 (100%)a |
Age (years, median, Q1-Q3) | 48 (44–54) | 48 (43–54) | 49 (44–54) |
Caucasian race | 35 (100%) | 21 (100%) | 14 (100%) |
BMI (Kg/m2) | 25.6 (22.2-27.2) | 25.3 (21.6-27.5) | 25.8 (24.1-26.9) |
Risk Group | |||
Ex-intravenous drug users | 8 (23%) | 7 (33%) | 1 (7%) |
Men-having-sex-with-men | 21 (57%) | 7 (33%) | 13 (93%) |
Heterosexual infection | 6 (17%) | 6 (29%) | 0 |
Vertical infection | 1 (3%) | 1 (5%) | 0 |
HIV infection variables | |||
Previous AIDS-defining events | 9 (25%) | 7 (33%) | 2 (14%) |
Nadir CD4+ T-cells/μL (median, Q1-Q3) | 94 (37–197) | 80 (34–140) | 188 (77–258) |
Current CD4+ T-cells/μL (median, Q1-Q3) | 577 (406–726) | 485 (374–686) | 624 (527–740) |
VL < 40 c/mL | 34 (97%) | 21 (100%) | 13 (93%) |
Hepatitis C virus coinfection | 4 (11%) | 4 (19%) | 0 |
VACS Index | 12 (5–19) | 16 (6–24) | 9 (0–12) |
Smoking and Treatments | |||
Smokers | 8 (23%) | 6 (29%) | 2 (14%) |
2NRTI + Protease inhibitor | 14 (40%) | 7 (33%) | 7 (50%) |
2NRTI + NNRTI | 11 (31%) | 7 (33%) | 4 (29%) |
Other ART regimens | 10 (28%) | 7 (33%) | 3 (21%) |
Beta blockersb | 6 (17%) | 5 (24%) | 1 (7%) |
Other anti-hypertensive drugsb | 5 (14%) | 2 (10%) | 3 (21%) |
Statinsb | 10 (29%) | 4 (19%) | 6 (42%) |
Fibratesb | 2 (6%) | 0 | 2 (14%) |
Inclusion Criteria | |||
Lipodystrophy | 35 (100%) | 21 (100%) | 14 (100%) |
≥ 1 metabolic syndrome criterion | 32 (91%) | 19 (90%) | 13 (93%) |
Blood triglycerides ≥150 mg/dL | 14 (40%) | 8 (38%) | 6 (42%) |
Blood HDL-C ≤40 (m) or ≤50 (w) mg/dL | 12 (34%) | 9 (43%) | 3 (21%) |
Blood glucose ≥110 mg/dL | 1 (3%) | 0 | 1 (7%) |
Waist ≥102 (m) or ≥88 (w) cm | 10 (28%) | 8 (38%) | 2 (14%) |
SBP ≥150 or DBP ≥85 mmHg | 12 (34%) | 7 (33%) | 5 (36%) |